Section 232 Pharma Tariff Cut for UK Products: CBP Guidance

CBP Issues Filing Guidance on UK Pharmaceutical Tariff Reductions

On August 2, 2026, U.S. Customs and Border Protection (CBP) published CSMS #69415934, providing operational guidance for importers and brokers on reduced tariffs affecting patented pharmaceuticals and associated pharmaceutical ingredients that are products of the United Kingdom.

What Changed

The reduction stems from an amendment to Presidential Proclamation 11020, "Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients Into the United States." On July 31, 2026, the Secretary of Commerce published the action that triggered this tariff adjustment. The proclamation specifically covers patented pharmaceuticals and their associated pharmaceutical ingredients originating in the United Kingdom. Importers of those product categories will see a lower duty rate applied to qualifying UK-origin shipments.

This is a Section 232-based action, meaning the rate change flows from a national-security trade remedy, not from a standard trade agreement or MFN schedule adjustment. As a result, accurate country-of-origin determination and correct HTS classification remain critical to correctly applying the reduced rate rather than the standard Section 232 column.

Why This Matters for Your Entries

Rate reductions under presidential proclamations take effect on a specific date tied to the proclamation's language. Entries filed before or after that effective date may carry different duty liability. Misclassified or incorrectly coded entries, whether paying too much or too little, can trigger liquidation adjustments, protests, or post-entry audits. Brokers filing on behalf of pharmaceutical importers should confirm:

• That the product qualifies as a patented pharmaceutical or associated pharmaceutical ingredient under the proclamation's scope.
• That the goods are properly documented as products of the United Kingdom for country-of-origin purposes.
• That the correct HTS classification and any required special program indicators or additional duty codes are applied in ACE consistent with CBP's CSMS guidance.

Importers with entries filed around the July 31, 2026 effective date should review whether those entries reflected the updated rate, and consider whether a post-summary correction or protest is warranted if duties were overpaid.

What importers should do

• Review CSMS #69415934 in full and share it with your classification and entry teams immediately.
• Confirm that UK-origin patented pharmaceuticals and pharmaceutical ingredients in your import pipeline are classified correctly and reflect the reduced rate on new entries.
• Audit entries filed on or around July 31, 2026 to identify any overpayments that may be recoverable through a post-summary correction or protest.
• Update your tariff-management system to flag UK pharmaceutical shipments for the amended proclamation rate going forward.